MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced the weight loss effects of Qnexa in subjects with type 2 diabetes at The Obesity Society Annual Scientific Meeting in Phoenix, Arizona. Dr. Barbara Troupin, Senior Director of Clinical Development, announced the data in a poster presentation titled “The Weight Loss Effects of VI-0521 in Type 2 Diabetes.” On an intent-to-treat basis, subjects treated with Qnexa, an investigational drug, for 28 weeks had a mean weight loss of approximately 17 pounds or 8 percent of their starting body weight, as compared to subjects treated with placebo who had weight loss of approximately 2.9 pounds or 1.2 percent (p<0.0001). In the study, 61 percent of the patients treated with Qnexa had weight loss of 5 percent as compared to 14 percent of the patients in the placebo group (p<0.0001).
